{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:08:57Z","timestamp":1770448137351,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T00:00:00Z","timestamp":1476748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Immunex Corporation, a wholly owned subsidiary of Amgen Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40801-016-0093-2","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T12:01:09Z","timestamp":1476792069000},"page":"369-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"3","author":[{"given":"Tao","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek H.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra F.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,18]]},"reference":[{"key":"93_CR1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/imt.13.94","volume":"5","author":"FM Meier","year":"2013","unstructured":"Meier FM, Frerix M, Hermann W, M\u00fcller-Ladner U. Current immunotherapy in rheumatoid arthritis. Immunotherapy. 2013;5:955\u201374.","journal-title":"Immunotherapy."},{"key":"93_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5435\/00124635-201201000-00004","volume":"20","author":"MS Day","year":"2012","unstructured":"Day MS, Nam D, Goodman S, Su EP, Figgie M. Psoriatic arthritis. J Am Acad Orthop Surg. 2012;20:28\u201337.","journal-title":"J Am Acad Orthop Surg."},{"key":"93_CR3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","volume":"48\u201349","author":"SP Raychaudhuri","year":"2014","unstructured":"Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun. 2014;48\u201349:128\u201333.","journal-title":"J Autoimmun."},{"key":"93_CR4","first-page":"546","volume":"8","author":"LH Kircik","year":"2009","unstructured":"Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol. 2009;8:546\u201359.","journal-title":"J Drugs Dermatol."},{"key":"93_CR5","unstructured":"ORENCIA\u00ae (abatacept) Prescribing Information. Princeton: Bristol-Myers Squibb Company; 2015."},{"key":"93_CR6","unstructured":"Humira\u00ae (adalimumab) Prescribing Information. North Chicago: AbbVie Inc.; 2014."},{"key":"93_CR7","unstructured":"CIMZIA\u00ae (certolizumab pegol) Prescribing Information. Smyrna: UCB, Inc.; 2013."},{"key":"93_CR8","unstructured":"Enbrel\u00ae (etanercept) Prescribing Information. Thousand Oaks: lmmunex Corporation; 2015."},{"key":"93_CR9","unstructured":"SIMPONI\u00ae (golimumab) Prescribing Information. Horsham: Janssen Biotech, Inc.; 2014."},{"key":"93_CR10","unstructured":"Remicade\u00ae (infliximab) Prescribing Information. Malvern: Janssen Biotech, Inc.; 2015."},{"key":"93_CR11","unstructured":"RITUXAN\u00ae (rituximab) Prescribing Information. South San Francisco: Genentech, Inc.; 2014."},{"key":"93_CR12","unstructured":"ACTEMRA\u00ae (tocilizumab) Prescribing Information. South San Francisco: Genentech, Inc.; 2014."},{"key":"93_CR13","unstructured":"STELARA\u00ae (ustekinumab) Prescribing Information. Horsham: Janssen Biotech, Inc.; 2014."},{"key":"93_CR14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138.","journal-title":"JAMA."},{"key":"93_CR15","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1002\/art.34680","volume":"64","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012;64:3850\u20135.","journal-title":"Arthritis Rheum."},{"key":"93_CR16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nu\u00f1o L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1445\u201352.","journal-title":"Rheumatology (Oxford)."},{"key":"93_CR17","unstructured":"Donahue KE, Jonas D, Hansen RA, Roubey R, Jonas B, Lux LJ, et al. Drug therapy for rheumatoid arthritis in adults: an update. Comparative Effectiveness Review No. 55. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I.) AHRQ Publication No. 12-EHC025-EF. Rockville: Agency for Healthcare Research and Quality; 2012. Available from: http:\/\/effectivehealthcare.ahrq.gov\/index.cfm\/search-for-guides-reviews-and-reports\/?productid=1042&pageaction=displayproduct . Accessed 23 Apr 2013."},{"key":"93_CR18","unstructured":"Donahue KE, Jonas D, Hansen RA, Roubey R, Jonas B, Lux LJ, et al. Drug therapy for psoriatic arthritis in adults: update of a 2007 report. 12-EHC024-EF. Rockville: Agency for Healthcare Research and Quality; 2012. Available from: http:\/\/effectivehealthcare.ahrq.gov\/ehc\/products\/464\/1043\/arthritis-psoriatic-executive-120424.pdf . Accessed 07 Aug 2015."},{"key":"93_CR19","doi-asserted-by":"crossref","unstructured":"Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.","DOI":"10.1002\/14651858.CD005468.pub2"},{"key":"93_CR20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3111\/13696998.2013.820192","volume":"16","author":"M Bonafede","year":"2013","unstructured":"Bonafede M, Joseph GJ, Princic N, Harrison DJ. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ. 2013;16:1120\u20138.","journal-title":"J Med Econ."},{"key":"93_CR21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12325-012-0007-y","volume":"29","author":"MM Bonafede","year":"2012","unstructured":"Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29:234\u201348.","journal-title":"Adv Ther."},{"key":"93_CR22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3111\/13696998.2011.644645","volume":"15","author":"VF Schabert","year":"2012","unstructured":"Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15:264\u201375.","journal-title":"J Med Econ."},{"key":"93_CR23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.18553\/jmcp.2013.19.8.621","volume":"19","author":"VF Schabert","year":"2013","unstructured":"Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19:621\u201330.","journal-title":"J Manag Care Pharm."},{"key":"93_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2013.856314","volume":"17","author":"AT Joyce","year":"2014","unstructured":"Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-na\u00efve rheumatoid arthritis patients in US health plans. J Med Econ. 2014;17:1\u201310.","journal-title":"J Med Econ."},{"key":"93_CR25","first-page":"1236","volume":"20","author":"A Howe","year":"2014","unstructured":"Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014;20:1236\u201344.","journal-title":"J Manag Care Spec Pharm."},{"issue":"1231\u201341","key":"93_CR26","first-page":"e3","volume":"36","author":"N Wu","year":"2014","unstructured":"Wu N, Lee YC, Shah N, Harrison DJ. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin Ther. 2014;36(1231\u201341):e3.","journal-title":"Clin Ther."},{"key":"93_CR27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/CEOR.S61445","volume":"6","author":"M Bonafede","year":"2014","unstructured":"Bonafede M, Joseph GJ, Shah N, Princic N, Harrison DJ. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. Clinicoecon Outcomes Res. 2014;6:381\u20138.","journal-title":"Clinicoecon Outcomes Res."},{"key":"93_CR28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.clinthera.2009.04.002","volume":"31","author":"DA Ollendorf","year":"2009","unstructured":"Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31:825\u201335.","journal-title":"Clin Ther"},{"key":"93_CR29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.18553\/jmcp.2015.21.4.318","volume":"21","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm. 2015;21:318\u201329.","journal-title":"J Manag Care Spec Pharm"},{"key":"93_CR30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.clinthera.2014.05.062","volume":"36","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36:996\u20131004.","journal-title":"Clin Ther"},{"key":"93_CR31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3111\/13696998.2014.914031","volume":"17","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. J Med Econ. 2014;17:555\u201366.","journal-title":"J Med Econ"},{"key":"93_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u2013278.","journal-title":"Health Technol Assess"},{"key":"93_CR33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","volume":"29","author":"M Bonafede","year":"2012","unstructured":"Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29:664\u201374.","journal-title":"Adv Ther."},{"key":"93_CR34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3111\/13696998.2011.649325","volume":"15","author":"CT Carter","year":"2012","unstructured":"Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ. 2012;15:332\u20139.","journal-title":"J Med Econ."},{"key":"93_CR35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1524-4733.2010.00764.x","volume":"13","author":"P Li","year":"2010","unstructured":"Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13:805\u201312.","journal-title":"Value Health."},{"key":"93_CR36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12325-014-0110-3","volume":"31","author":"J Yeaw","year":"2014","unstructured":"Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31:410\u201325.","journal-title":"Adv Ther."},{"key":"93_CR37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12325-012-0039-3","volume":"29","author":"B Chastek","year":"2012","unstructured":"Chastek B, Fox KM, Watson C, Gandra SR. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012;29:691\u20137.","journal-title":"Adv Ther."},{"key":"93_CR38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/09546634.2012.661038","volume":"24","author":"B Chastek","year":"2013","unstructured":"Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24:25\u201333.","journal-title":"J Dermatolog Treat"},{"key":"93_CR39","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1016\/j.jval.2013.03.135","volume":"16","author":"T Wasser","year":"2013","unstructured":"Wasser T, Wu B, Ycas J, Tunceli O, Cziraky MJ. Comparison of commercial insurance databases to census data for age, gender and geographic region in the United States. Value Health. 2013;16:A22\u20133.","journal-title":"Value Health"},{"key":"93_CR40","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/art.21582","volume":"53","author":"SK Agarwal","year":"2005","unstructured":"Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum. 2005;53:872\u20138.","journal-title":"Arthritis Rheum."},{"key":"93_CR41","first-page":"26","volume":"29","author":"RJ Moots","year":"2011","unstructured":"Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol. 2011;29:26\u201334.","journal-title":"Clin Exp Rheumatol."},{"key":"93_CR42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2474-12-204","volume":"12","author":"S Ogale","year":"2011","unstructured":"Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204.","journal-title":"BMC Musculoskelet Disord."},{"key":"93_CR43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3111\/13696998.2012.667028","volume":"15","author":"MM Bonafede","year":"2012","unstructured":"Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic na\u00efve rheumatoid arthritis patients in commercial managed-care plans in the 2\u00a0years following therapy initiation. J Med Econ. 2012;15:635\u201343.","journal-title":"J Med Econ."},{"key":"93_CR44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1185\/03007995.2012.656844","volume":"28","author":"VF Schabert","year":"2012","unstructured":"Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin. 2012;28:569\u201380.","journal-title":"Curr Med Res Opin."},{"key":"93_CR45","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3899\/jrheum.140164","volume":"41","author":"GW Cannon","year":"2014","unstructured":"Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, et al. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol. 2014;41:1935\u201343.","journal-title":"J Rheumatol."},{"key":"93_CR46","first-page":"2014","volume-title":"U.S. Census Bureau, Current Population Reports, P60\u2013250, Health Insurance Coverage in the United States","author":"JC Smith","year":"2013","unstructured":"Smith JC, Medalia C. U.S. Census Bureau, Current Population Reports, P60\u2013250, Health Insurance Coverage in the United States. Washington, DC: US Government Printing Office; 2013. p. 2014."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-016-0093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-016-0093-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-016-0093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T16:20:24Z","timestamp":1657470024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-016-0093-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,18]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1007\/s40801-016-0093-2","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,18]]}}}